Previous studies have demonstrated that interleukina (IL-1a) inhibits glucocorticoid receptor (GR) nuclear translocation and dexamethasone (Dex)-induced gene transcription. Given that IL-1a is a potent activator of the p38 mitogen-activated protein kinase (MAPK) signal transduction pathway and p38 MAPK has been associated with reduced GR function, we examined the role of p38 MAPK in IL-1a-mediated inhibition of GR function in mouse fibroblast cells stably transfected with a GR-mediated reporter gene construct (LMCAT cells). Treatment of LMCAT cells with IL-1a (1000 U/ml) for 24 h inhibited Dex (50 nM)-induced GRE-CAT activity by B35%. When cells were cotreated for 24 h with IL-1a plus SB-203580 (0.5-1 lM), a selective p38 inhibitor, IL-1a's inhibitory effect on GR function as determined by Dex-induced GRE-CAT activity was reversed. Using gel mobility shift assay, SB-203580 was also found to reverse IL-1a inhibition of GR-GRE binding. Further confirming the role of p38 pathways, pretreatment of LMCAT cells with antisense oligonucleotides targeted to p38 MAPK completely abrogated IL-1a inhibition of Dex-induced GRE-CAT activity. Taken together, these results demonstrate that activation of p38 MAPK pathways are involved in IL-1a-mediated inhibition of GR function. In addition, these findings extend the intracellular targets of p38 to include the GR and indicate that p38 inhibitors may have special utility in immunologic and/or neuropsychiatric disorders associated with impaired GR-mediated feedback inhibition. Molecular Psychiatry (2004) 9, 65-75. doi:10.1038/sj.mp.4001339
Substantial data provide evidence that glucocorticoid receptor (GR) function is reduced in patients with major depression. 1, 2 These data are derived primarily from in vivo and in vitro challenge tests that have examined the ability of glucocorticoids (presumably through their receptors) to feedback negatively on relevant neuroendocrine and immune responses that are under glucocorticoid control. In vivo challenge tests using the synthetic glucocorticoid, dexamethasone (Dex), have reliably demonstrated nonsuppression of cortisol in depressed patients after oral administration of Dex in the context of both the Dex suppression test and the Dex/corticotrophin releasing hormone (CRH) test. In vitro studies have also demonstrated reduced responsiveness to glucocorticoids in peripheral blood mononuclear cells from depressed patients, obviating concerns that in vivo tests are solely related to alterations in Dex bioavailability and/or increased hypothalamic drive. Consequences of altered GR function in major depression may include hypersecretion of CRH as well as overactivation of the immune response, both of which may contribute to the behavioral and physiological alterations of the disorder. 2, 3 Although the mechanism(s) of GR alterations in major depression are unknown, consideration has been given to the possibility that proinflammatory cytokines may be involved. 2, 3 Emerging evidence has shown that major depression is associated with inflammation/immune activation with associated increases of proinflammatory cytokines (including IL-1 and IL-6) in blood and cerebrospinal fluid. 4 Moreover, elevations in blood IL-1 have been correlated with post-Dex cortisol concentrations, suggesting a direct relation between proinflammatory cytokine concentrations and impaired glucocorticoid-mediated feedback inhibition. 3, 5 Proinflammatory cytokines are also potent inducers of a syndrome of sickness behavior that has many features in common with major depression, including anhedonia, anorexia, fatigue, sleep disturbance, and impaired cognition, and therefore may contribute to the behavioral features of the disorder. 3, 6 Nevertheless, of most relevance to the GR are studies demonstrating that proinflammatory cytokines can directly inhibit GR function. 3 Exposure of cells to proinflammatory cytokines has been shown to decrease cell sensitivity to the effects of glucocorticoids on various functional end points [7] [8] [9] as well as decrease GR affinity for ligand. 7, [10] [11] [12] Additionally, studies performed on peripheral cells and tissues of patients with inflammatory diseases, such as asthma, ulcerative colitis, acquired immunodeficiency syndrome, and rheumatoid arthritis, especially those exhibiting resistance to the therapeutic effects of glucocorticoids, have demonstrated reductions in GR function and affinity. 10, [13] [14] [15] Of note, these inflammatory disorders also have been found to exhibit a high rate of comorbid depression. [16] [17] [18] [19] [20] In exploring the mechanism of the effects of cytokines on GR, work in our laboratory has shown that the proinflammatory cytokine, interleukin 1a (IL1a), inhibits the translocation of the GR from cytosol to nucleus and reduces Dex-induced, GR-mediated gene transcription. 21 In addition, IL-1a administration was associated with evidence of increased cellular concentrations of GR protein, as manifested by increased GR binding and increased GR immunostaining (especially in the cytoplasm). The signal transduction pathways that are involved in these effects of IL-1 have yet to be elucidated. One possibility includes IL-1 activation of mitogen-activated protein kinases (MAPK). 22, 23 Through binding to the IL-1/toll-like receptor (TLR), IL-1 is well known to activate MAPK signaling pathways including the p38 MAPK pathway, as evidenced by increased phosphorylation of ATF2 24 and heat shock protein 27. 25 Of note, in a recent report, activation of p38 MAPK pathways was found to result in GR phosphorylation that in turn was associated with reduced sensitivity to glucocorticoids. 26 To further investigate the molecular mechanism(s) by which IL-1a inhibits GR function, we set out to examine the role of IL-1a-induced activation of p38 MAPK pathways. Experiments were conducted in a mouse fibroblast cell line (LMCAT cells) stably transfected with the mouse mammary tumor viruschloramphenicol acetyltransferase (MMTV-CAT) reporter gene. Cells were treated with IL-1a for 24 h in the presence or absence of the synthetic steroid, Dex and/or SB-203580, a selective p38 inhibitor. Antisense oligonucleotides targeted to p38 MAPK were also used to examine the involvement of p38 pathways. GR function was measured by means of GRmediated gene transcription in LMCAT cells. In addition, GR-GRE binding from different treatments was determined using gel mobility shift assay, and GR mRNA levels were quantitated using real-time PCR. 
Materials and methods

Chemicals
Cell culture
Mouse fibroblast LMCAT cells stably transfected with a construct containing MMTV and CAT reporter gene were generously provided by Dr ER Sanchez (Medical College of Ohio, Toledo, OH, USA). Cells were grown in 175-cm 2 flasks in DMEM medium (Invitrogen Corporation, Carlsbad, CA, USA) with 10% stripped newborn calf serum (NCS) (charcoal/dextran-extracted, heat-inactivated) at 371C with 5% CO 2 in ambient air. The stably transfected GRE-CAT reporter construct was maintained in the presence of 0.2 mg/ ml G418 sulfate (geneticin) antibiotic. For drug treatment experiments, cells were subcultured in six-well plates and grown for 24 h to 95% confluence. Appropriate vehicle controls were used in all the experiments, and each experimental condition included at least three replicates.
CAT assay CAT concentrations induced by Dex were measured using the commercial CAT ELISA kit from Roche Diagnostics (Indianapolis, IN, USA). Before assay, the cells were washed three times with cold 1 Â PBS and then lysed with the provided buffer after incubation at room temperature for 30 min. Cell extracts were then spun at 23 000 Â g at 41C for 10 min to remove cellular debris. The supernatant was collected and stored at À801C until assayed. CAT assay was performed following manufacturer's instructions. Briefly, antibodies to CAT were precoated on the surface of the microtiter plate modules. Cell extracts were then added to the wells to allow CAT in the cell extracts to bind specifically to the precoated anti-CAT antibodies. A digoxigenin conjugated to peroxidase was added to bind to digoxigenin on anti-CAT antibodies. After incubation for 1 h, CAT concentrations were determined by colorimetry (absorption at 405 nm against the reference wavelength of 492 nm) using a VERSAmax tunable microtiter plate reader from Molecular Devices (Sunnyvale, CA, USA). resuspended in 1 ml of PBS, transferred to a 1.5 ml Eppendorf tube and centrifuged for 30 s at 10 000 Â g (41C). The cell pellets were resuspended in 50 ml of cold, low-salt buffer (containing 20 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM Na 3 VO 4 , 1 mM EDTA, 1 mM EGTA, 0.2% Nonidet P-40, 10% glycerol, 0.5 mM PMSF, and 1 mM DTT) and mixed by gentle pipetting. After 15 min incubation on ice, cell pellets were centrifuged at 13 000 g for 2 min (41C), and the supernatants were discarded. The nuclei pellets were suspended in 50 ml ice-cold high salt buffer (containing 20 mM HEPES, pH 7.9, 420 mM NaCl, 10 mM KCl, 0.1 mM Na 3 VO 4, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 0.5 mM PMSF, and 1 mM DTT) and vigorously rocked at 41C for 30 min. The nuclear extracts were collected after centrifugation at 13 000 g for 30 min (41C) and stored at À801C for later analysis.
Intracellular
Protein concentration determination
Protein concentrations were determined using a commercial bicinchoninic acid (BCA) kit from Pierce (Rockford, IL, USA) following the manufacturer's instructions. Briefly, protein samples were alkalized with the supplied reagent and incubated with the reaction reagent containing Cu 2 þ to produce purple color for colorimetric detection against BSA protein standard. 
Gel shift assay
RNA isolation
Total RNA was isolated from cells grown in 60-mm culture dishes after different treatments for 24 h as described. Cells were washed with 1 Â ice-cold PBS once, and 1 ml of Trizol reagent (Invitrogen Corporation, Carlsbad, CA, USA) was directly added into the dish to lyse cells. Cell lysates were incubated for 5 min at RT to permit complete dissociation of nucleoprotein complexes. Then 0.2 ml of chloroform was added, and samples were vortexed vigorously for 1 min. RNA samples were precipitated and washed following the manufacturer's instructions. After brief air-drying at RT, RNA samples were dissolved in RNase-free water, and their concentrations and A260/ 280 ratio were determined using the MBA 2000 System (Perkin-Elmer, Shelton, CT, USA).
Real-time PCR analysis
Changes in GR gene transcription were analyzed using real-time PCR technique, GeneAmp 7000 Sequence Detection System from Applied Biosystems (Norwalk, CT, USA). Briefly, 2 mg total RNA isolated from different treatments of cultured cells was reverse transcribed using SuperScriptt First-strand Synthesis System for RT-PCR from Invitrogen (Carlsband, CA, USA) using random primers following the manufacturer's instructions. Primers for mouse GR and 18S rRNA gene were designed using Primer Express software with T m at 591C and G/C content in the 20-80% range. The primers used for the amplification of the mouse GR gene were 5 0 -ACC TGG ATG ACC AAA TGA CC (forward) and 5 0 -TTG GCT CTT CAG ACC TTC CT (reverse), corresponding to nucleotides 1799-1818 and 2066-2085 of the mouse GR cDNA. PCR reaction was carried out using SYBR Green PCR Master Mix from Applied Biosystems after optimization of primer concentrations, template concentrations and PCR cycles. In brief, 20 ng RT product was mixed with 5 ml SYBR Green PCR Master Mix and specific primers (300 nM) in a total volume of 10 ml. The reactions in 96-well plate were held at 501C for 2 min and 951C for 10 min, followed by thermal cycling for 40 cycles at 951C for 15 s and 601C for 1 min. The quantitation of the GR gene was analyzed using the included software against the standard and normalized against 18S ribosomal RNA.
p38 antisense oligonucleotide treatment Phosphorothiolate-modified antisense oligonucleotides specific for p38-MAPK (5 0 -GTC TTG TTC AGC TCC TGC-3 0 ) as well as sense (5 0 -GCA GGA GCT GAA CAA GAC-3 0 ) oligonucleotides 27 were synthesized. Cells were incubated with 1 mM of each oligonucleotide in serum-free RPMI 1640 for 6 h before addition of 10% charcoal stripped/heat-inactivated NCS. After 24 h of culture, cells were treated with either vehicle control, or Dex in the presence or absence of IL-1a, and cells were prepared for CAT assay as described above.
Western blot analysis of p38 protein Antibodies against p38-MAPK or phospho-p38-MAPK were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). After different treatments, cells were directly lysed in the culture dishes using 500 ml of lysing buffer (containing 20 mM Tris, pH 7.5; 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin, 1 mM PMSF). Cell lysates were sonicated and p38 MAPK inhibition of GR function X Wang et al centrifuged at 15 000 rpm for 10 min at 41C. Protein (50 mg) from each group was mixed with SDS sample buffer and separated by a 12% SDS-PAGE, transferred to nitrocellulose membrane, and probed with the first antibody (1/1000 dilution) at room temperature for 3 h. Bound primary Ab was detected by horseradish peroxidase-conjugated secondary antibody (1 : 2000 dilution), protein bands were visualized using a commercially available chemoluminescence kit from Amersham Biosciences Corp. (Piscataway, NJ, USA).
p38-MAPK activity measurement p38 MAP Kinase Assay kit was purchased from Cell Signaling Technology, Inc. Cells were directly lysed in the culture dishes. Cell lysates were sonicated and centrifuged at 15 000 rpm for 10 min at 41C as above. The supernatant containing equivalent amounts of protein (200 mg) was incubated by gentle rocking with 20 ml of immobilized phospho-p38-MAPK monoclonal antibody for 16 h at 41C. The immunoprecipitates were washed twice with the lysing buffer and pelleted by centrifugation. The p38-MAPK assay was carried out using ATF-2 fusion protein (2 mg) as a substrate in the presence of 200 mM ATP and 1 Â kinase buffer following the manufacturer's recommendations. Samples were resolved on a 12% SDS-PAGE gel and visualized by autoradiography.
Data analysis and statistics
Descriptive statistics (including the mean and standard deviation) were used to characterize the dependent measures in all experiments. One-or two-way analysis of variance (ANOVA) was used to assess for main effects and interactions of treatment conditions and/or dose and/or time. For all ANOVAs, both the Student-Newman-Keuls method and the Student's t-test were used for post hoc tests of differences between specific means in order to include both a conservative (Student-Newman-Keuls) and a powerful (Student's t-test) assessment of statistical significance. The level of significance was set at Po0.05, and all tests of significance were two-tailed.
Results
IL-1a induces p38 activity as measured by phosphorylation of ATF2 and MAPKAPK-2 kinase As shown in Figure 1 , IL-1a significantly induced p38 activity in mouse fibroblasts as evidenced by increased expression of phosphorylated ATF2 (Panels A and B) as well as increased expression of phosphorylated MAPKAPK-2 kinase (Panel C), both of which are substrates of activated p38 MAPK. Interestingly, however, when cells were pretreated with SB-203580 (1 mM), a selective p38 inhibitor, for 1 h, IL-1a-induced p38 activity as reflected by phosphorylated ATF2 was unchanged (Panel B), whereas IL-1a-induced MAPKAPK-2 phosphorylation was significantly blocked by SB-203580 at both 1 and 10 mM. Similar results have been reported by others in which only endogenous MAPKAPK-2 phosphorylation was inhibited by SB-203580 using in vitro assay. 28 Selective p38 inhibitor, SB-203580, reverses IL-1a inhibition of GRE-CAT activity and GR-GRE binding As shown in Figure 2 , there was a significant main effect of treatment condition on GRE-CAT activity (F [6, 14] ¼ 120.8, Po0.0001). Treatment with IL-1a (1000 U/ml) for 24 h led to significant inhibition of Dex-induced GRE-CAT activity by B35%. When cells were cotreated with IL-1a plus SB-203580 (1 mM) for 24 h, IL-1a-mediated inhibition of GRE-CAT activity was significantly attenuated. SB-203580 alone (1 mM) had no effects on Dex-induced GRE-CAT activity. To examine the effects of IL-1a and SB-203580 on GR DNA binding, nuclear extracts were obtained from LMCAT cells after treatment with Dex alone or in combination with IL-1a and/or SB-203580. Results from gel mobility shift assay (see Figure 3 ) using synthetic [ p38 MAPK inhibition of GR function X Wang et al
GR-GRE binding (lane 4)
. These results were replicated in at least three independent experiments.
Effect of IL-1a and SB-203580 on GR mRNA expression To determine whether IL-1a inhibition of GRmediated gene transcription and SB-203580 attenuation of IL-1a inhibitory effects were associated with changes in GR mRNA levels, total RNA was isolated from LMCAT cells treated with IL-1a in the presence or absence of Dex and/or SB-203580. Real-time PCR was used with specific primers to mouse GR cDNA, and 18S rRNA was used as the internal loading standard. As depicted in Figure 4 , there was a significant main effect of treatment condition (F [7, 16] ¼ 63.9, Po0.0001) on GR mRNA levels. Cells treated with IL-1a for 24 h exhibited a slight but significant increase in GR mRNA. Of note, the addition of SB-203580 (1 mM) had no effect on IL-1a-induced changes. SB-203580 alone (1 mM) significantly increased GR mRNA. Dex plus IL-1a reversed the effects of IL-1a alone.
Effect of SB-203580 on GR function and the p-glycoprotein pump Based on gel shift assay, SB-203580 plus IL-1a and Dex exhibited evidence of some enhancement of GR Fold Induction * * ** ** Figure 4 Effect of IL-1a and SB-203580 on GR mRNA levels. Total RNA was isolated from LMCAT cells after 24 h treatment with IL-1a (1000 U/ml) with or without cotreatment with SB-203580 (1 mM) or 1.5 h treatment with Dex (50 nM). RNA was reverse-transcribed and 20 ng RT products were used from each treatment. PCR reaction was carried out using SYBR Green PCR Master Mix. The quantitation of the GR gene was analyzed using the included software against the standard and normalized against 18S ribosomal RNA. IL-1a caused 25% (Po0.01) increase of GR mRNA compared with the control, and cotreatment with SB-203580 had no additional effects on IL1a's induction. SB-203580 alone also caused significant increase of GR mRNA levels by 60% (Po0.001) and the combination of SB-203580 and IL-1a had no additional effects.
p38 MAPK inhibition of GR function X Wang et al DNA binding over Dex alone. Moreover, as noted above, SB-203580 alone significantly increased GR mRNA. These data suggested some independent effect of SB-203580 on the GR. To further investigate independent effects of SB-203580 on GR activity, LMCAT cells were treated with various concentrations of SB-203580 (0.1, 0.5, 1, and 10 mM) for 24 h, and Dex (50 nM) was added 1.5 h before harvest for CAT assay. There was a significant main effect of treatment condition (F [5, 12] ¼ 636.3, Po0.0001). Interestingly, SB-203580 significantly enhanced Dex-induced CAT activity at 10 mM but not at lower concentrations ( Figure 5 ). SB-203580 at higher dose (30 mM) has been reported to increase significantly intracellular accumulation of [ 3 H]-vincristine in multidrug resistant L1210/VCR mouse leukemic cell line by inhibition of the pglycoprotein pump, 29 the effects of SB-203580 on intracellular dexamethasone (also a substrate for the p-glycoprotein pump) in LMCAT cells in the presence of various concentrations of SB-203580 was examined. As shown in Figure 6 , there was a significant main effect of treatment condition on intracellular [ 3 H]Dex concentrations (F [5, 12] ¼ 277.3, Po0.0001).
Treatment of LMCAT cells with SB-203580 for 24 h increased intracellular [
3 H]Dex concentrations by 14, 16, and 60%, at the dosages of 0.5, 1, and 10 mM, respectively. SB-203580 at 0.1 mM had no effect on intracellular [ centration accounted for SB-203580-enhancement of GR activity, we examined the effects of SB-203580 on GRE-CAT activity in LMCAT cells treated with Cort, which is not a substrate for pump. 30 Although less pronounced than the effects on Dex, SB-203580 also significantly enhanced Cort-induced GRE-CAT activity by 16 and 32%, respectively, at concentrations of 5 and 10 mM, but not at 1 mM (Figure 7 ) (F [4, 10] ¼ 68.7, Po0.0001).
p38 antisense oligonucleotide treatment reduces p38 protein levels and reverses IL-1a inhibition of GR function and IL-1a-induced p38 phosphorylation Given the direct effects of SB-203580 on the GR, the role of p38 pathways in IL-1a-mediated GR inhibition was further explored using antisense oligonucleotides targeting p38 MAPK. Cells were pretransfected with 1 mM antisense oligonucleotide for 24 h, and p38 and phospho-p38 were measured by Western blotting. As seen in Figure 8a and b, both p38 and phospho-p38 levels were significantly reduced in the antisense treatment groups vs the sense or nonoligo control groups. When cells were pretransfected with 1 mM antisense oligonucleotide for 24 h, IL-1a-mediated GR inhibition was completely reversed (Po0.01). The p38 sense oligonucleotide had no significant effects on IL-1a-mediated GR inhibition (P40.05) (see Figure  9 ). Of note, p38 antisense oligonucleotide treatment alone noticeably enhanced basal GRE-CAT activity (Po0.05). 
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To determine the role of p38 in the effect of higher doses of SB-203580 (X10 mM) on GR function, LMCAT cells were treated with SB-203580 in the presence and absence of p38 antisense oligonucleotides. As shown in Figure 10 , antisense oligonucleotides had no effect on SB-203580 (10 mM) enhancement of Dex-induced GRE-CAT activity, further confirming an effect of SB-203580 on GR function independent of its activity on p38.
Discussion
Consistent with our previous studies, the results of these experiments demonstrate that IL-1a significantly inhibits GR-mediated gene transcription and GR-GRE binding. Relevant to the mechanism of these effects, IL-1a inhibitory effects on GR function were significantly attenuated by inhibition of p38 activity using SB-203580, a selective p38 MAPK inhibitor, and were completely reversed by antisense oligonucleotides targeted to p38, indicating that p38 MAPK pathways are involved in IL-1a-mediated GR functional impairment.
Proinflammatory cytokines such as IL-1 bind to their membrane receptors and activate MAPK pathways including p38, ERK, and JNK as well as the NFkB pathway. 31 Activation of p38 MAPK has been reported to play a pivotal role in cytokine production (IL-1, TNFa, and IL-2), 32 ,33 cytokine-induced cell proliferation 34 and apoptosis caused by osmotic shock or ultraviolet irradiation. 35 The signaling pathway by which IL-1 activates p38 pathways is not yet fully understood, although it has been proposed that the early events of signal transduction are similar to IL-1 activation of NF-kB and JNK. Briefly, IL-1 binds to IL-1 type I receptor on the cell membrane and forms a complex with the IL-1 receptor accessory protein (IL1RAcP), triggering the association of an adaptor protein myeloid differentiation factor 88 (MyD88). MyD88 then interacts with IL-1 receptor-associated kinase (IRAK), subsequently causing IRAK phosphorylation. Phosphorylated IRAK forms a complex with tumor necrosis factor receptor-associated factor 6 (TRAF-6), resulting in the phosphorylation of transforming growth factor-b-activated kinase-1 (TAK1).
36
TAK1 is reported to be an upstream kinase of MKK6 and MKK3, 37 both of which are upstream kinases of p38 MAPK.
Although the data suggest that p38 pathways are involved in IL-1a-induced GR impairment, the exact molecular mechanism has yet to be established. A recent study demonstrated that activation of p38 by combined treatment of human peripheral blood mononuclear cells with IL-2 and IL-4 was associated Figure 8 The effect of p38 antisense oligonucleotide on p38 and phospho-p38. LMCAT cells were grown in 60-mm culture dishes until 80% confluent. Cells were then tranfected with p38 antisense or sense oligonucleotide (1 mM) using lipofectin from Amersham for 24 h. Cells were treated with vehicle control or with IL-1a (1000 U/ml) for various times as indicated. Cells were harvested using lysing buffer, and 50 mg protein from each group was loaded and separated on a 12% SDS-PAGE and transferred to a nitrocellulose membrane. p38 (a) and phosphorylated p38 (b) levels were determined using monoclonal antibodies from Cell Signaling as described in the Materials and methods. (a) Antisense transfection reduced p38 levels in both vehicle and IL-1a treatment groups vs sense or nonoligonucleotide transfection control groups. (b) Antisense transfection reduced phosphorylated p38 levels in both vehicle and IL-1a treatment groups vs the sense group. A representative experiment of three replicates is shown.
p38 MAPK inhibition of GR function X Wang et al with phosphorylation of the GR and reduced GR function. 26 Although it could not be determined whether GR phosphorylation was a direct effect of p38 MAPK, phosphorylation at hGR serine 226 was reversed using SB-203580. It should be noted that many p38 target proteins may be involved in disrupted GR function including the immediate downstream kinase, MAPK-activated protein kinase 2 and 3 (MAPKAPK-2, -3), 38, 39 CREB, 40 hsp-27, 25, 38 ATF2, 24 Elk1, 41 CHOP, 42 and Max. 43 For example, overexpression of CREB has been found to inhibit GR transactivation in placenta cells, 44 and CREB activation by treatment with high concentrations of b2-adrenoceptor agonist inhibits GR-GRE binding in rat lung. 45 Given the multiple steps in both GR and p38 signaling pathways, it is also possible that other GR co-factors/repressors or p38 target proteins such as nuclear transcription factors may participate in IL-1a-induced GR impairment. Of note, previous studies have implicated NF-kB in disruption of GR function, primarily through protein-protein interactions. 46, 47 Nevertheless, data from this study suggest that p38 pathways are just as relevant to GR regulation, in that the effects of IL-1, which activates NF-kB in concert with p38, were completely reversed by specifically targeting p38 pathways, while leaving NF-kB signal transduction ostensibly intact. Thus, in some cell types (eg microglia), where IL-1 activates p38 phosphorylation without effects on NF-kB pathways, IL-1 may predominately influence GR function through activation of p38 signaling pathways. 48 Interestingly, p38 MAPK has been reported to interact with other members of the steroid receptor superfamily including the estrogen receptor 49 and retinoid acid receptor g 50 as well as other nuclear receptors such as peroxisome proliferator-activated receptor a 51 and transcription coactivator PGC-1.
52
These results suggest that there may be shared mechanisms among these effects on steroid hormone receptors.
In further evaluation of the effects of SB-203580 on p38 activity as well as the GR, it is apparent that this compound does not block all p38 activities under all experimental conditions and has effects on the GR that are independent of its antagonism of p38. SB-203580 treatment failed to inhibit phosphorylation of exogenous ATF-2 by immunoprecipitated p38. A similar finding was reported by Baldassare et al., 28 who hypothesized that 'the intracellular interaction of the inhibitor with the catalytic domain of p38 may The effect of p38 antisense oligonucleotide on IL1a-mediated inhibition of MMTV-CAT activity. LMCAT cells were treated with 1 mM phosphorothiolate-modified antisense oligonucleotides specific for p38-MAPK or sense oligonucleotides in serum-free RPMI 1640 for 6 h before addition of 10% charcoal stripped/heat-inactivated NCS for additional 18 h. Cells were then treated with either vehicle control, or Dex in the presence or absence of IL-1a as described. After treatment, cells were harvested for CAT assay as described. *IL-1a treatment caused 35% (Po0.001) inhibition of Dex-induced GRE-CAT activity compared to Dex alone. aFPretreatment of cells with antisense p38 oligo significantly reversed IL-1a inhibition of GR function (Po0.001). Pretreatment with antisense or sense oligo had no effects on Dex-induced CAT activity (P40.05). Pretreatment with sense oligo had no significant additional effects on IL-1a inhibition of GR function (P40.05). Figure 10 The combined effect of p38 antisense oligonucleotide and SB-203580 on Dex-induced MMTV-CAT activity. LMCAT cells were treated with 1 mM phosphorothiolate-modified antisense oligonucleotides specific for p38-MAPK or sense oligonucleotides in serum-free RPMI 1640 for 6 h before addition of 5% charcoal stripped/heatinactivated FCS for additional 18 h. Cells were then treated with either vehicle control, or Dex (50 mM, 1.5 h) in the presence or absence of pretreatment with SB-203580 (10 mM). After treatment, cells were harvested for CAT assay as described. *SB treatment in the presence of the p38 sense or antisense oligonucleotide transfection caused significant further enhancement of Dex-induced GRE-CAT activity (Po0.001), 260 and 290%, respectively. 53 as well as the pglycoprotein mdr pump. 29 Taken together, the data indicate that SB-203580 has broad biological effects beyond p38 inhibition. According to the data reported herein, this broad activity extends to effects on the GR as manifested by (1) enhancement of Cort-induced GR-mediated gene transcription (an effect that is mdr pump independent because Cort is not a substrate for the pump) and (2) enhancement of Dex-induced GRmediated gene transcription in cells treated with p38 antisense oligonucleotides (thus eliminating any contribution of p38). Therefore, we cannot conclude that the effects of SB-203580 in reversing IL-1-mediated inhibition of GR function occur solely through blockade of p38 activity, complicating the interpretation of the experimental and/or clinical activity of this compound.
It should be noted that all of the experiments conducted as part of this study utilized fibroblasts. Fibroblasts have been widely used as models to study a number of biological activities, including the interaction of the GR with a variety of signaling pathways. [54] [55] [56] [57] [58] [59] In addition, human fibroblasts have been reported to contain receptors, second messengers, and protein kinase systems, which are similar to those found in other tissues including the brain. [60] [61] [62] Indeed, reduced PKA activity in fibroblasts from depressed patients 63 has also been reported in brain tissue from depressed individuals. 64 As previously discussed, activation of p38 activity by IL-2 plus IL-4 leading to impaired GR function was first described in peripheral blood mononuclear cells, further suggesting that the pathway from p38 to disrupted GR function generalizes to other cell types including immune cells. 26 Nevertheless, further studies must be conducted to determine the generalizability of the findings to other cell types including neurons.
Resistance to the effects of glucocorticoids not only exists in depression, but also appears in subgroups of patients with acute or chronic inflammatory diseases such as sepsis, asthma, ulcerative colitis, acquired immunodeficiency syndrome, rheumatoid arthritis, and allogenic organ transplantation who also exhibit high rates of depression. [16] [17] [18] [19] [20] 65 Although the molecular mechanism of glucocorticoid resistance is yet to be fully elucidated, its presence in disorders characterized by inflammation supports the potential role of inflammatory cytokines, including IL-1, and the activation of p38 MAPK pathways. Data from this study provide evidence that inhibitors of p38 MAPK signaling pathways may reverse the effects of inflammatory cytokines on the GR, thereby restoring glucocorticoid-mediated negative feedback on inflammatory responses. Moreover, through their activity on NF-kB signaling pathways, glucocorticoids are some of the most potent anti-inflammatory factors in the body. 66 Of note, p38 has become a target in the development of novel treatments for inflammatory disorders. For example, one recent report showed that oral administration of a p38 MAPK inhibitor (BIRB 796 BS) significantly inhibited LPS-induced cytokine production including TNFa, IL-6, and IL-10 in healthy volunteers. 67 Moreover, several widely used nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen) have been found to suppress T-cell activation through the inhibition of p38 MAPK pathways. 68 Finally, activation of the phosphatidyl serine receptor has been shown to reduce IL-1 activation of p38 MAPK, suggesting another interesting therapeutic target for abrogating IL-1 effects on GR function. 48 Taken together, the results provide evidence that pharmacological agents that have p38 inhibitory properties may not only be useful for the treatment of inflammatory immunologic disorders but also may have utility in neuropsychiatric disorders associated with inflammation and impaired GR-mediated feedback inhibition, including depression in the medically ill.
